https://dxm-atlas.org/en/interactions/ritonavir/
CompareKey points for this combination
Human tests that use substances to measure metabolic activity give different results across treatment regimens and measurements. They do not show a uniformly strong effect on the CYP2D6 enzyme [45, 46].
General concepts in this text
Enzyme
A protein that helps chemical transformations in cells.
A transformation can build or break down a substance.
Sources: Enzyme
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
Drug metabolism
Chemical transformation of a medicine in the body.
The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.
Sources: Drug metabolism
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
How well is this understood?
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
Can the amount reaching the body change?
ⓘ
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
ⓘ
CYP3A
A group of related CYP enzymes involved in the chemical transformation of medicines.
CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.
Sources: CYP3A
- Daly: Significance of the minor cytochrome P450 3A isoforms · Clin Pharmacokinet. 2006;45(1):13–31; DOI 10.2165/00003088-200645010-00002; PMID 16430309
- In a study of 13 healthy CYP2D6 extensive metabolizers, a low ritonavir booster regimen did not significantly change the urinary DXM/DXO metabolic ratio or convert participants to poor-metabolizer status. Finding below: Finding [45] · 3
- A different probe, desipramine, nevertheless detected modest CYP2D6 inhibition [45]. Finding below: Finding [45] · 1
- Plasma DXM-to-DXO AUC ratio increase → In a separate study of HIV-infected patients receiving ritonavir-boosted lopinavir, the plasma DXM-to-DXO AUC ratio increased 2.92-fold in extensive metabolizers [46]. Finding below: Finding [46]
What remains unknown?
The magnitude of the interaction depends on the regimen, population and measure studied. Direct pharmacokinetic results are presented with each study’s conditions; this heterogeneous group has its own row.
The 2.92-fold change concerns the ratio of two AUCs — DXM and DXO.
Sources
Check the review’s wording
- [45] Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers · Open publication
- [46] Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients · Open publication
Evidence and sources
Research publication
[45] · Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers · 2005
Finding [45] · 3
- What was found?
In a study of 13 healthy CYP2D6 extensive metabolizers, a low ritonavir booster regimen did not significantly change the urinary DXM/DXO metabolic ratio or convert participants to poor-metabolizer status.
Finding [45] · 2
Finding [45] · 1
- What was found?
A different probe, desipramine, nevertheless detected modest CYP2D6 inhibition [45].
- What limits this finding?
The magnitude of the interaction depends on the regimen, population and measure studied. Direct pharmacokinetic results are presented with each study’s conditions; this heterogeneous group has its own row.
Research publication
[46] · Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients · 2008
Finding [46]
- What was found?
In a separate study of HIV-infected patients receiving ritonavir-boosted lopinavir, the plasma DXM-to-DXO AUC ratio increased 2.92-fold in extensive metabolizers [46].
Plasma DXM-to-DXO AUC ratio increase
What do AUC, Cmax and DXO mean?
2.92-fold
- What limits this finding?
The 2.92-fold change concerns the ratio of two AUCs — DXM and DXO.